Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Verve Therapeutics Inc.
Headquarters: Cambridge, MA, United States of America
Website: https://www.vervetx.com
Year Founded: 2018
Status: Public
Industry Sector: HealthTechnology
CEO: Sekar Kathiresan, MD
Number Of Employees: 274
Enterprise Value: $23,535,642
PE Ratio: -1.67
Exchange/Ticker 1: NASDAQ:VERV
Exchange/Ticker 2: N/A
Latest Market Cap: $347,191,584
BioCentury | Mar 4, 2025
Deals
Kyorin picks Novartis amid innovative push; Abbvie taps Gubra for obesity: Deals Report
Plus: Hummingbird/Callio, Bridgene/Takeda, Magnet/Lilly, Gensaic/Novo, and more
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: New modality showdowns
Genetic therapies compete in the same indications, as degraders come of age
BioCentury | Jun 1, 2024
Management Tracks
Verve promotes Lister to CSO
Plus: Quantum-Si appoints Kummeth independent chair and updates from Alkeus and SAB
BioCentury | Apr 3, 2024
Product Development
Clinical report: getting behind Verve’s PCSK9 Phase I safety signal
Plus readouts from Gritstone, Disc, BMS and Novocure
BioCentury | Feb 14, 2024
Management Tracks
New CEOs for Enable, StromaCare
Plus: Philippakis joins GV as general partner, and updates from Verily, Meliora, Citryll and Silver Creek
BioCentury | Jan 20, 2024
Finance
Buysiders are all about market-creating catalysts in 2024
BioCentury’s 32nd Buyside View finds MASH, obesity and pain are among the year’s most closely-watched categories
BioCentury | Dec 23, 2023
Discovery & Translation
Taking next-gen mAbs to new heights will lead modality innovation
Execs and investors weigh in on which technologies will yield the biggest gains in innovation in the near term and beyond: BioCentury survey
BioCentury | Dec 21, 2023
Product Development
Diamonds in a rough 2023, predictions for 2024
BioCentury’s analysts look back at a year when innovation was hot but markets were not, and predict what’ll make news in 2024
BioCentury | Nov 30, 2023
Regulation
Nov. 29 Quick Takes: Karuna’s schizophrenia therapy gets FDA goal date
Plus: BioMarin to sell gene therapy in Germany for $2M less than U.S. and updates from Arrivo, Verve, Arcutis, Boehringer, Phenomic
BioCentury | Nov 14, 2023
Product Development
Verve’s choice of lead application left little room to impress
Company achieves landmark POC for base editing technology, but with safety concerns and efficacy of approved therapies already high, its shares take a hit
Items per page:
1 - 10 of 43